MOUNTAIN VIEW, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- IRIDEX Corporation ("Iridex", or the "Company") (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it has executed definitive agreements related to a private placement financing (the "Financing") of a senior convertible promissory note (the "Initial Note") with Lind Global Asset Management IX LLC, an ...

IRIDEX Corporation (NASDAQ:IRIX) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Trip Taylor - Investor Relations David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief Financial Officer Conference Call Participants Tom Stephan - Stifel Trip Taylor Thank you, and thank you all for participating in today's call. Joining me are David Bruce, Chief Executive Officer; and Fuad Ahmad, Interim Chief Financial Officer. Earlier today, IRIDEX released financial results for the ...

Iridex (IRIX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -75%. A quarter ago, it was expected that this medical laser company would post a loss of $0.05 per share when it actually produced a loss of $0.18, delivering a surprise of -260%. Over the last four quarters, the company has surp ...

Exhibit 99.1 Iridex Reports First Quarter 2024 Financial Results MOUNTAIN VIEW, Calif., May 14, 2024 -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 30, 2024, and provided a business update. First Quarter 2024 Financial Highlights "We saw some of the firming we expected during the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-27598 IRIDEX CORPORATION (Exact name of Registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdiction of in ...

We expect sales to stabilize throughout the year as orders are backfilled and the resumption of regular purchasing behavior from the glaucoma practices. Our retina segment revenue in Q4 was $7.5 million, a decrease of 7% compared to the prior year period. In the quarter, we continue to see elongated capital purchase cycles and distributor destocking. For the full year '23, retina product revenue was $29.4 million, down 7% compared to 2022. As customer capital purchase plans remain generally intact, we antic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-27598 IRIDEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0210467 (State or other jurisdict ...

The LCDs limit MIGS procedures concomitant with cataract surgery to a single device and specifically call out newer MIGS devices that enable both a canaloplasty and a goniotomy procedure to be performed with a single device. These and several other procedures were labeled as investigational, which means they were made ineligible for Medicare reimbursement until more rigorous clinical work on effectiveness is published. First, half of IRIDEX' glaucoma revenue is international and unaffected. Further, two of ...

Philip Taylor - Gilmartin Group David Bruce - President, CEO & Director Fuad Ahmad - Interim Chief Financial Officer Operator Philip Taylor Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact, ...

As we look at the remainder of 2023, we expect to improve the growth rate of our glaucoma business and increase utilization. We are reiterating our guidance and continue to expect to sell 65,000 to 67,000 probes, representing growth of 9% to 12% compared to 2022. And expect to grow the G6 installed base by 225 to 250 systems. Fuad Ahmad Operating expenses for the first quarter were $8.3 million, flat compared to the same period last year. Our net loss in the quarter of -- first quarter of 2023 was $2.1 mill ...